Get the Stockscreener App
5.44
44.03%
1.6491
Bioline Rx Ltd Adr stock is traded at $5.44, with a volume of 35.40M.
It is up +44.03% in the last 24 hours and up +57.35% over the past month.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
See More
Previous Close:
$3.7909
Open:
$5.87
24h Volume:
35.40M
Relative Volume:
63.09
Market Cap:
$12.11B
Revenue:
-
Net Income/Loss:
$-60.61M
P/E Ratio:
-6.0444
EPS:
-0.9
Net Cash Flow:
$-22.91M
1W Performance:
+49.18%
1M Performance:
+57.35%
6M Performance:
+1,738%
1Y Performance:
+566.02%
1-Day Range:
$5.04
$7.7699
1-Week Range:
$3.43
$7.7699
52-Week Range:
$0.0815
$7.7699
Bioline Rx Ltd Adr Stock (BLRX) Company Profile
Compare BLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BLRX
Bioline Rx Ltd Adr
|
5.4232 | 14.14M | 0 | -60.61M | -22.91M | -0.90 |
|
ONC
Beone Medicines Ltd Adr
|
246.59 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.52 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.52 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
491.05 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Bioline Rx Ltd Adr Stock (BLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-18-17 | Upgrade | Maxim Group | Hold → Buy |
| Feb-13-17 | Initiated | Rodman & Renshaw | Buy |
| Aug-12-16 | Downgrade | Maxim Group | Buy → Hold |
| Aug-17-15 | Reiterated | Maxim Group | Buy |
| Jul-27-15 | Reiterated | ROTH Capital | Buy |
| Jun-22-15 | Initiated | JMP Securities | Mkt Outperform |
View All
Bioline Rx Ltd Adr Stock (BLRX) Latest News
BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating By Stocktwits - Investing.com India
BioLineRx announces new data from Phase 2 combination trial of motixafortide - TipRanks
Jones Trading raises BioLineRx stock rating, targets $12 By Investing.com - Investing.com India
Jones Trading raises BioLineRx stock rating, targets $12 - Investing.com
BioLineRx upgraded to Buy from Hold at JonesResearch - TipRanks
BioLineRx Presents Promising Phase 2 Data at ASCO 2025 for Pancreatic Cancer Trial - TipRanks
BioLineRx reports promising pancreatic cancer trial data By Investing.com - Investing.com India
BioLineRx reports promising pancreatic cancer trial data - Investing.com
BioLineRx ADR: Positive Earnings Call Highlights and Challenges - MSN
Jones Trading maintains Hold on BioLineRx stock amid royalty prospects By Investing.com - Investing.com India
H.C. Wainwright Maintains Buy Rating, $26 Target on BioLineRx Stock - Investing.com
BioLineRx: Strong Financials and Promising Clinical Developments Drive Buy Rating - TipRanks
BioLineRx Ltd. Reports Q1 2025 Financial Results - TipRanks
BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident By Stocktwits - Investing.com India
BioLineRx Reports Q1 2025 Financial Results and Strategic Updates - TipRanks
Options Volatility and Implied Earnings Moves Today, May 27, 2025 - TipRanks
BioLineRx Ltd. Schedules Annual Shareholder Meeting for June 2025 - TipRanks
Analysts Offer Insights on Healthcare Companies: VYNE Therapeutics (VYNE) and CVRx (CVRX) - The Globe and Mail
BioLineRx stock rating cut to Hold at Jones Trading - Investing.com
BLRX stock touches 52-week low at $2.85 amid sharp annual decline - Investing.com
H.C. Wainwright raises BioLineRx stock target to $26 - Investing.com India
BioLineRx Ltd. Reports 2024 Financial Results and Strategic Progress - TipRanks
BioLineRx Earnings Call: Strategic Shifts and Growth - TipRanks
BioLineRx price target adjusted to $26 at H.C. Wainwright after reverse split - TipRanks
Options Volatility and Implied Earnings Moves This Week, March 31 – April 03, 2025 - The Globe and Mail
BioLineRx Reports Strong 2024 Financial Results and Strategic Advancements - TipRanks
Options Volatility and Implied Earnings Moves Today, March 31, 2025 - TipRanks
Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire
Investor Network: Bioline RX Ltd Sponsored ADR to Host Earnings Call - ACCESS Newswire
BLRX: Aphexda Transition Progressing - Research Tree
BioLineRx stock hits 52-week low at $3.24 amid sharp decline - Investing.com India
BioLineRx announces strategic shift with licensing deals - Investing.com
BioLineRx Outlines Strategic Vision and Financial Outlook After Key Licensing Deals - TipRanks
BioLineRx Adjusts ADS Ratio to Maintain Nasdaq Listing - TipRanks
BioLineRx Announces 1:40 ADS Ratio Change, Confirms $29.5M Cash Runway Through 2026 - Stock Titan
BioLineRx stock touches 52-week low at $0.14 amid downturn - Investing.com India
BioLineRx stock touches 52-week low at $0.14 amid downturn By Investing.com - Investing.com South Africa
BiolineRx Announces Major Direct Offering to Bolster Operations - TipRanks
BioLineRx stock plunges to 52-week low of $0.19 amid market challenges - Investing.com
BioLineRx Announces $10 Million Direct Offering to Fuel Growth - TipRanks
BioLineRx Raises $10M in Direct Offering at $0.20 Per ADS with Matching Warrants - Stock Titan
BioLineRx stock hits 52-week low at $0.21 amid market challenges - Investing.com
BioLineRx stock plunges to 52-week low, hits $0.25 - Investing.com India
BioLineRx stock target cut, retains buy on Q3 financial results - Investing.com
BioLineRx Reports Strategic Moves in Q3 2024 - TipRanks
BioLineRx earnings beat by $0.04, revenue topped estimates By Investing.com - Investing.com South Africa
Earnings call: BioLineRx announces Q3 results and strategic shifts - Investing.com
Earnings call: BioLineRx announces Q3 results and strategic shifts By Investing.com - Investing.com South Africa
BioLineRx Secures Key Deals to Boost Shareholder Value - TipRanks
BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell - Yahoo Finance
BiolineRx Ltd. Announces New Direct Offering of Shares - TipRanks
Bioline Rx Ltd Adr Stock (BLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):